Silexion initiates Phase 2/3 trial of SIL204 in pancreatic cancer at Tel Aviv Sourasky Medical Center

Silexion Therapeutics Corp

First clinical site activated at Tel Aviv Sourasky Medical Center; patient screening to begin in coming weeks.
Phase 2/3 trial of SIL204 (siRNA) for locally advanced pancreatic cancer; follows regulatory approvals from Israeli MoH and German BfArM.
Trial includes safety run-in (~18 patients) then randomized cohort (~166 patients); dual-route administration (intratumoral + systemic).
Additional Israeli and German sites expected to join in coming months; first patient dosing anticipated as next milestone.
SIL204 targets broad range of KRAS mutations; KRAS mutations present in ~90% of pancreatic cancers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.